Peters R E, Janossy G, Ivory K, al-Ismail S, Mercolino T
Department of Clinical Immunology, Royal Free Hospital School of Medicine, London, UK.
Leukemia. 1994 Nov;8(11):1864-70.
Normal and malignant B-lymphoid cells were studied for CD37 antigen expression with three-color immunofluorescence (IF) in combination with kappa/lambda light chain staining, and by quantitative immunofluorescence utilizing the QIFI test. Peripheral B cells brightly expressed CD37 antigen (median 80-114 x 10(3) molecules/cell). Moderate to high levels (> 20 x 10(3)/cell) of CD37 expression were detected in 364 in 366 cases of peripheral B-cell disorders including all cases of B-ALL, B-cell lymphomas and B-CLL as well as eight of ten cases of PLL. By contrast, slg- B-cell precursors and other cell types in normal bone marrow (BM) were CD37-/CD37dull (< 10 x 10(3) molecules/cell). The negativity for CD37 or only CD37dull expression was confirmed in 180 of 182 cases of precursor B-ALL and 196 cases of non-B malignancies. Among the CD37 cluster, the RFB7 antibody of IgM class showed the weakest binding to non-B cells. In 64 normal samples of blood and BM the CD37+ gated cells showed normal kappa/lambda ratios as expected, while in 100 cases of B malignancy striking changes such as kappa/lambda monoclonality (79%) and aberrant slg- or sigdull expression (21%) were seen among the gated CD37+ B cells. The CD37/kappa/lambda test identified as few as 0.5% kappa+ or lambda- monoclonal B cells admixed to normal BM: circulating B-lymphoma cells were seen in nine patients with morphologically normal blood count. The discrimination of the Kolmogorov-Smirnov (KS) test for kappa/lambda excess was also improved by CD37+ B gating. Thus CD37+ B-cell gating and kappa/lambda analysis is a simple and sensitive routine test, e.g. when combined with autogating on a Cytoron-Absolute cytometer, for identifying malignant B cells in minimally involved BM and blood.
采用三色免疫荧光（IF）结合κ/λ轻链染色，并利用QIFI试验进行定量免疫荧光，对正常和恶性B淋巴细胞进行CD37抗原表达研究。外周血B细胞高表达CD37抗原（中位数为80 - 114×10³分子/细胞）。在366例外周血B细胞疾病中的364例中检测到中等至高水平（>20×10³/细胞）的CD37表达，包括所有B - ALL、B细胞淋巴瘤和B - CLL病例以及十例PLL中的八例。相比之下，正常骨髓（BM）中的sIg⁻ B细胞前体和其他细胞类型为CD37⁻/CD37暗淡（<10×10³分子/细胞）。在182例前体B - ALL和196例非B恶性肿瘤病例中，180例证实CD37阴性或仅为CD37暗淡表达。在CD37抗体组中，IgM类的RFB7抗体与非B细胞的结合最弱。在64例正常血液和骨髓样本中，CD37⁺门控细胞显示出预期的正常κ/λ比值，而在100例B恶性肿瘤病例中，在门控的CD37⁺ B细胞中观察到显著变化，如κ/λ单克隆性（79%）和异常的sIg⁻或sIg暗淡表达（21%）。CD37/κ/λ试验可识别出混入正常骨髓中的低至0.5%的κ⁺或λ⁻单克隆B细胞：在9例血细胞形态正常的患者中发现了循环B淋巴瘤细胞。通过CD37⁺ B门控，Kolmogorov - Smirnov（KS）试验对κ/λ过量的鉴别能力也得到了提高。因此，CD37⁺ B细胞门控和κ/λ分析是一种简单而敏感的常规检测方法，例如与Cytoron - Absolute细胞仪上的自动门控相结合时，可用于识别微小受累骨髓和血液中的恶性B细胞。
